HomeASRT • NASDAQ
Assertio Holdings Inc
add
$0.64
4.51%
After Hours:(0.00%)0.00
$0.64
Closed: May 15, 7:02:16 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 31.65M | 27.15% |
Net income | -13.54M | -200.24% |
Net profit margin | -51.12 | -267.77% |
Earnings per share | -0.04 | -200.00% |
EBITDA | — | — |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 87.33M | 8.15% |
Total assets | 286.43M | 1.58% |
Total liabilities | 177.90M | 20.63% |
Total equity | — | — |
Shares outstanding | 95.77M | — |
Price to book | 0.54 | — |
Return on assets | -11.33% | — |
Return on capital | -20.96% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -13.54M | -200.24% |
Cash from operations | — | — |
Cash from investing | -2.94M | — |
Cash from financing | — | — |
Net change in cash | -15.58M | -313.42% |
Free cash flow | -8.44M | -190.76% |
Previous close
$0.61
Day range
$0.62 - $0.64
Year range
$0.51 - $1.80
Market cap
61.44M USD
Avg Volume
379.35K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration. On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor. Wikipedia
Founded
1995
Headquarters
Website
Employees
58
